The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Justin Edge Biography and Net Worth

Insider of Certara

Mr. Edge is the president of Synchrogenix, Certara’s regulatory science division. Synchrogenix provides a wide range of services and technologies to support sponsors throughout the regulatory process, including developing and submitting all the requisite documents for new drug, medical device and biologics applications. Prior to joining Certara, Justin worked at GfK, a leading global research and analytics firm with 13,000 employees, where he most recently led the company’s healthcare business unit, managing teams in more than 20 countries. A 25 year industry veteran, Justin is a frequent conference speaker, chair and contributor for Eye for Pharma, ARF, EphMRA, PBIRG, PMRG, CRC, and others.

What is Justin Edge's net worth?: The estimated net worth of Justin Edge is at least $7.18 million as of August 30th, 2021. Mr. Edge owns 433,090 shares of Certara stock worth more than $7,176,301 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Edge may own. Learn More about Justin Edge's net worth.
How do I contact Justin Edge?: The corporate mailing address for Mr. Edge and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Justin Edge's contact information.
Has Justin Edge been buying or selling shares of Certara?: Justin Edge has not been actively trading shares of Certara in the last ninety days. Most recently, Justin Edge sold 5,000 shares of the business's stock in a transaction on Thursday, January 20th. The shares were sold at an average price of $27.50, for a transaction totalling $137,500.00. Learn More on Justin Edge's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

Justin Edge Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/20/2022	Sell	5,000	$27.50	$137,500.00
10/21/2021	Sell	6,116	$38.60	$236,077.60
9/27/2021	Sell	3,000	$36.00	$108,000.00
8/30/2021	Sell	9,000	$33.50	$301,500.00	433,090
6/16/2021	Sell	5,000	$27.02	$135,100.00	447,090

Justin Edge Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $16.57

$16.25

$16.77

50 Day Range

MA: $17.72

$15.93

$19.45

2 Week Range

Now: $16.57

$11.81

$24.64

Volume

321,546 shs

Average Volume

533,271 shs

Market Capitalization

$2.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63